biotech / news / / STAT
We hope the weekend respite was relaxing and invigorating.
U.S. biotech firms spent $60 billion on Chinese drug molecules in early 2026 alone.
KEY POINTS
- This spending is set to double last year's total, which was ten times 2021's amount.
- China's rapid drug development and low costs are fueling U.S. companies' dependence.
- The surge creates a rift over whether Chinese firms are partners or competitors in biotech.
COMPANIES
Summarized by Newsio from STAT. How we summarize →